<article article-type="research-article"> 
 <!--?properties open_acces=""?--> 
 <!-- Original-type: oa--> 
 <front> 
  <journal-meta> 
   <journal-id journal-id-type="nlm-ta">
     Br J Cancer 
   </journal-id> 
   <journal-h3>
     British Journal of Cancer 
   </journal-h3> 
   <issn pub-type="ppub">
     0007-0920 
   </issn> 
   <issn pub-type="epub">
     1532-1827 
   </issn> 
   <publisher> 
    <publisher-name>
      Nature Publishing Group 
    </publisher-name> 
   </publisher> 
  </journal-meta> 
  <article-meta> 
   <article-id pub-id-type="pmid">
     15928660 
   </article-id> 
   <article-id pub-id-type="pmc">
     2361800 
   </article-id> 
   <article-id pub-id-type="pii">
     6602598 
   </article-id> 
   <article-id pub-id-type="doi">
     10.1038/sj.bjc.6602598 
   </article-id> 
   <article-categories> 
    <subj-group subj-group-type="heading"> 
     <subject>
       Molecular Diagnostics 
     </subject> 
    </subj-group> 
   </article-categories> 
   <h3-group> 
    <article-h3>
      Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of 
     <italic>
       BRAF 
     </italic> or 
     <italic>
       RAS 
     </italic> 
    </article-h3> 
   </h3-group> 
   <contrib-group> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Zuidervaart 
      </surname> 
      <given-names>
        W 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        van Nieuwpoort 
      </surname> 
      <given-names>
        F 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Stark 
      </surname> 
      <given-names>
        M 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Dijkman 
      </surname> 
      <given-names>
        R 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Packer 
      </surname> 
      <given-names>
        L 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Borgstein 
      </surname> 
      <given-names>
        A-M 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Pavey 
      </surname> 
      <given-names>
        S 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        van der Velden 
      </surname> 
      <given-names>
        P 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Out 
      </surname> 
      <given-names>
        C 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Jager 
      </surname> 
      <given-names>
        M J 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Hayward 
      </surname> 
      <given-names>
        N K 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Gruis 
      </surname> 
      <given-names>
        N A 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
     <xref ref-type="corresp" rid="caf1">
       * 
     </xref> 
    </contrib> 
   </contrib-group> 
   <aff id="aff1"> 
    <label>1</label>Department of Ophthalmology, Leiden University Medical Centre, PO Box 9600, 2300 RC, Leiden, The Netherlands 
   </aff> 
   <aff id="aff2"> 
    <label>2</label>Department of Dermatology, Leiden University Medical Centre, Wassenaarseweg 72, 2333 AL, Leiden, The Netherlands 
   </aff> 
   <aff id="aff3"> 
    <label>3</label>Queensland Institute of Medical Research, 300 Herston Rd, Herston, QLD 4029, Australia 
   </aff> 
   <author-notes> 
    <corresp id="caf1"> 
     <label>*</label>Author for correspondence: 
     <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:gruis@lumc.nl">
       gruis@lumc.nl 
     </email> 
    </corresp> 
   </author-notes> 
   <pub-date pub-type="epub"> 
    <day>
      31 
    </day> 
    <month>
      05 
    </month> 
    <year>
      2005 
    </year> 
   </pub-date> 
   <pub-date pub-type="ppub"> 
    <day>
      06 
    </day> 
    <month>
      06 
    </month> 
    <year>
      2005 
    </year> 
   </pub-date> 
   <volume>
     92 
   </volume> 
   <issue>
     11 
   </issue> 
   <fpage>
     2032 
   </fpage> 
   <lpage>
     2038 
   </lpage> 
   <history> 
    <date date-type="received"> 
     <day>
       01 
     </day> 
     <month>
       12 
     </month> 
     <year>
       2004 
     </year> 
    </date> 
    <date date-type="rev-recd"> 
     <day>
       10 
     </day> 
     <month>
       03 
     </month> 
     <year>
       2005 
     </year> 
    </date> 
    <date date-type="accepted"> 
     <day>
       24 
     </day> 
     <month>
       03 
     </month> 
     <year>
       2005 
     </year> 
    </date> 
   </history> 
   <copyright-statement>
     Copyright 2005, Cancer Research UK 
   </copyright-statement> 
   <copyright-year>
     2005 
   </copyright-year> 
   <permissions> 
    <copyright-holder>
      Cancer Research UK 
    </copyright-holder> 
   </permissions> 
   <abstract> 
    <h3>Abstract</h3> 
    <p>In contrast to cutaneous melanoma, there is no evidence that 
     <italic>
       BRAF 
     </italic> mutations are involved in the activation of the mitogen-activated protein kinase (MAPK) pathway in uveal melanoma, although there is increasing evidence that this pathway is activated frequently in the latter tumours. In this study, we performed mutation analysis of the 
     <italic>
       RAS 
     </italic> and 
     <italic>
       BRAF 
     </italic> genes in a panel of 11 uveal melanoma cell lines and 19 primary uveal melanoma tumours. In addition, Western blot and immunohistochemical analyses were performed on downstream members of the MAPK pathway in order to assess the contribution of each of these components. No mutations were found in any of the three RAS gene family members and only one cell line carried a 
     <italic>
       BRAF 
     </italic> mutation (V599E). Despite this, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), ERK and ELK were constitutively activated in all samples. These data suggest that activation of the MAPK pathway is commonly involved in the development of uveal melanoma, but occurs through a mechanism different to that of cutaneous melanoma.</p> 
   </abstract> 
   <kwd-group> 
    <kwd>
      MAPK pathway 
    </kwd> 
    <kwd>
      uveal melanoma 
    </kwd> 
    <kwd> 
     <italic>
       BRAF 
     </italic> 
    </kwd> 
    <kwd> 
     <italic>
       RAS 
     </italic> 
    </kwd> 
    <kwd>
      mutation 
    </kwd> 
   </kwd-group> 
  </article-meta> 
 </front> 
 <p>Uveal melanoma is the most common primary intraocular tumour in adults, with an annual incidence of 6?8 new cases per million among Caucasian populations. Up to half of all patients die from metastatic disease ( 
  <xref ref-type="other" rid="bib10">
    Diener-West 
   <italic>
     et al 
   </italic>, 1992 
  </xref>). In spite of several known prognostic markers (pathologic and genetic), such as tumour cell type, diameter, localisation and cytogenetic abnormalities, little is known about specific genes associated with predisposition and progression in uveal melanoma ( 
  <xref ref-type="other" rid="bib23">
    Mooy and de Jong, 1996 
  </xref>; 
  <xref ref-type="other" rid="bib34">
    Sisley 
   <italic>
     et al 
   </italic>, 1997 
  </xref>). Notable exceptions are hypermethylation of 
  <italic>
    CDKN2A 
  </italic>, which is more common in tumours from patients who develop metastatic disease ( 
  <xref ref-type="other" rid="bib40">
    van der Velden 
   <italic>
     et al 
   </italic>, 2001 
  </xref>), and germline 
  <italic>
    BRCA2 
  </italic> gene mutations, which occur in 3% of patients younger than 50 years of age ( 
  <xref ref-type="other" rid="bib31">
    Scott 
   <italic>
     et al 
   </italic>, 2002 
  </xref>). Hence, the search for other genes and molecular pathways involved in uveal melanoma development is of great significance. In contrast to uveal melanoma, the influence of specific pathways in cutaneous melanoma, which shares the same embryonic origin, is better defined. For instance, the tumour suppressor gene 
  <italic>
    PTEN 
  </italic>, encoding a dual-specific phosphatase and a member of the PI3-AKT pathway, plays a major role in the pathogenesis of cutaneous melanoma ( 
  <xref ref-type="other" rid="bib15">
    Guldberg 
   <italic>
     et al 
   </italic>, 1997 
  </xref>; 
  <xref ref-type="other" rid="bib36">
    Stahl 
   <italic>
     et al 
   </italic>, 2003 
  </xref>), whereas no mutations in this gene have been found in uveal melanoma ( 
  <xref ref-type="other" rid="bib25">
    Naus 
   <italic>
     et al 
   </italic>, 2000 
  </xref>).</p> 
 <p>Recently, the RAS-RAF-MEK-ERK or mitogen-activated protein kinase (MAPK) pathway has been found to play an important role in melanocytic neoplasia ( 
  <xref ref-type="other" rid="bib6">
    Cohen 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib30">
    Satyamoorthy 
   <italic>
     et al 
   </italic>, 2003 
  </xref>). Activation of this pathway in cutaneous melanocytes has been shown to occur by a variety of mechanisms, including autocrine growth factor stimulation and mutation of the 
  <italic>
    RAS 
  </italic> or 
  <italic>
    BRAF 
  </italic> genes. Of three 
  <italic>
    RAS 
  </italic> genes found to be activated by mutation in human tumours, 
  <italic>
    NRAS 
  </italic> (neuroblastoma RAS viral (v- 
  <italic>
    ras 
  </italic>) oncogene homologue) is most commonly mutated in cutaneous melanomas ( 
  <xref ref-type="other" rid="bib41">
    van Elsas 
   <italic>
     et al 
   </italic>, 1996 
  </xref>). In the active GTP-bound state, RAS activates a number of downstream signalling cascades involved in controlling cell growth and behaviour. Initially, RAS interacts with and activates the serine/threonine protein kinase BRAF that acts in the MAPK pathway to transduce regulatory signals from RAS to mitogen-activated protein kinase/extracellular signal-related kinase kinase (MEK1/2). The signal transducer MEK1/2 phosphorylates extracellular signal-regulated kinase (ERK1/2, p44/42), leading to the activation of these kinases, which in turn activate a variety of transcription factors, including ELK1, again through phosphorylation. It has emerged that 
  <italic>
    BRAF 
  </italic> (v- 
  <italic>
    raf 
  </italic> murine sarcoma viral oncogene homologue B1) is very frequently activated by mutation in cutaneous melanomas ( 
  <xref ref-type="other" rid="bib2">
    Brose 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib8">
    Davies 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib1">
    Alsina 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib11">
    Dong 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib13">
    Gorden 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib18">
    Kumar 
   <italic>
     et al 
   </italic>, 2003a 
  </xref>, 
  <xref ref-type="other" rid="bib19">
    2003b 
  </xref>; 
  <xref ref-type="other" rid="bib21">
    Maldonado 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib26">
    Omholt 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib27">
    Pollock 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib29">
    Rimoldi 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib30">
    Satyamoorthy 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib42">
    Weber 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib5">
    Cohen 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib28">
    Reifenberger 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib33">
    Shinozaki 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib38">
    Tsao 
   <italic>
     et al 
   </italic>, 2004 
  </xref>). The frequency of 
  <italic>
    BRAF 
  </italic> mutations varies from 8 to 83% depending on the anatomic site of the lesion and its histogenic subtype. Notably, the frequency of 
  <italic>
    BRAF 
  </italic> mutations is also high in benign melanocytic naevi ( 
  <xref ref-type="other" rid="bib11">
    Dong 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib27">
    Pollock 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib39">
    Uribe 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib43">
    Yazdi 
   <italic>
     et al 
   </italic>, 2003 
  </xref>), indicating that constitutive activation of the MAPK pathway is an early event in melanomagenesis. All 
  <italic>
    BRAF 
  </italic> mutations in cutaneous pigmented neoplasms occur within the kinase domain. The most frequently found mutation in 
  <italic>
    BRAF 
  </italic> (V599E) consists of a 1796T ? A transversion in exon 15 ( 
  <xref ref-type="other" rid="bib8">
    Davies 
   <italic>
     et al 
   </italic>, 2002 
  </xref>). Various other mutations have been described in this exon in melanocytic tumours (V599D ( 
  <xref ref-type="other" rid="bib2">
    Brose 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib8">
    Davies 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib27">
    Pollock 
   <italic>
     et al 
   </italic>, 2003 
  </xref>); V599K ( 
  <xref ref-type="other" rid="bib27">
    Pollock 
   <italic>
     et al 
   </italic>, 2003 
  </xref>, 
  <xref ref-type="other" rid="bib39">
    Uribe 
   <italic>
     et al 
   </italic>, 2003 
  </xref>); V599R ( 
  <xref ref-type="other" rid="bib27">
    Pollock 
   <italic>
     et al 
   </italic>, 2003 
  </xref>); K600E ( 
  <xref ref-type="other" rid="bib2">
    Brose 
   <italic>
     et al 
   </italic>, 2002 
  </xref>, 
  <xref ref-type="other" rid="bib30">
    Satyamoorthy 
   <italic>
     et al 
   </italic>, 2003 
  </xref>)). All other mutations have been described in exon 11. The latter consist of a 1352A ? C transversion (K438Q) ( 
  <xref ref-type="other" rid="bib2">
    Brose 
   <italic>
     et al 
   </italic>, 2002 
  </xref>), a 1402G ? A transition (G468R) and a 1402/1403GG ? TC tandem transversion ( 
  <xref ref-type="other" rid="bib13">
    Gorden 
   <italic>
     et al 
   </italic>, 2003 
  </xref>), a 1394G ? A transition (G465E) and a 1394G ? C transversion (G465A) ( 
  <xref ref-type="other" rid="bib8">
    Davies 
   <italic>
     et al 
   </italic>, 2002 
  </xref>). Furthermore, it is not surprising that since they activate the same pathway, mutations in 
  <italic>
    NRAS 
  </italic> and 
  <italic>
    BRAF 
  </italic> are almost mutually exclusive ( 
  <xref ref-type="other" rid="bib2">
    Brose 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib8">
    Davies 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib1">
    Alsina 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib11">
    Dong 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib13">
    Gorden 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib18">
    Kumar 
   <italic>
     et al 
   </italic>, 2003a 
  </xref>, 
  <xref ref-type="other" rid="bib19">
    2003b 
  </xref>; 
  <xref ref-type="other" rid="bib26">
    Omholt 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib27">
    Pollock 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib30">
    Satyamoorthy 
   <italic>
     et al 
   </italic>, 2003 
  </xref>; 
  <xref ref-type="other" rid="bib28">
    Reifenberger 
   <italic>
     et al 
   </italic>, 2004 
  </xref>; 
  <xref ref-type="other" rid="bib38">
    Tsao 
   <italic>
     et al 
   </italic>, 2004 
  </xref>).</p> 
 <p>Since cutaneous and uveal melanoma both arise from neural crest-derived melanocytes, we sought to assess whether the MAPK pathway was similarly activated in melanoma of the uvea. We thus screened for activating mutations in the 
  <italic>
    NRAS 
  </italic>, 
  <italic>
    HRAS 
  </italic>, 
  <italic>
    KRAS 
  </italic> and 
  <italic>
    BRAF 
  </italic> genes in uveal melanoma cell lines and primary uveal melanomas. Sequence analysis was performed on exons 11?15 of 
  <italic>
    BRAF 
  </italic>, and exons 1 and 2 of the three 
  <italic>
    RAS 
  </italic> family members, which cover the positions of all known mutations of these genes in all types of cancer. In addition, we performed immunohistochemistry and Western blot analysis with MEK, ERK and ELK antibodies both on cell lines and/or primary tumours to assess the level of expression and degree of activation of these proteins in order to provide insight into the involvement of this pathway in the development of uveal melanoma.</p> 
 <sec sec-type="materials|methods"> 
  <h3>MATERIALS AND METHODS</h3> 
  <sec> 
   <h3>Cell lines and primary uveal melanoma specimens</h3> 
   <p><span style="background-color:#ff0000">In total, 11 uveal melanoma cell lines, derived from primary uveal melanomas (Mel202, Mel 285, Mel 270, Mel 290, Ocm 1, Ocm 3, 92.1, 92.2) or uveal melanoma metastases (Omm 1 Omm 1.3 and Omm 1.5), were analysed</span>. <span style="background-color:#ff1c1c">Mel 202, Mel 285, Mel 270, Mel 290 and the two cell lines derived from metastases (Omm 1.3 and Omm 1.5) were kindly provided by Dr BR Ksander (Schepens Eye Institute, Boston, MA, USA)</span>. <span style="background-color:#ffd4d4">Omm 1, obtained from a subcutaneous metastasis, was established by Dr Luyten ( Luyten et al , 1996 )</span>. <span style="background-color:#ff6e6e">The cell lines Ocm 1 and Ocm 3 were provided by Dr Kan-Mitchell ( Kan-Mitchell et al , 1989 ) and cell lines 92.1 and 92.2, derived from the same primary tumour were established in our own laboratory ( de Waard-Siebinga et al , 1995 )</span>. <span style="background-color:#ffeeee">The melanoma cell lines were cultured in RPMI 1640 (Gibco, Paisley, Scotland) medium, supplemented with 3?m M L -glutamine (Gibco), 2% penicillin/streptomycin and 10% FBS (Hyclone, Logan, UT, USA)</span>. <span style="background-color:#fff8f8">All cell cultures were incubated at 37?C in a humidified 5% CO2 atmosphere</span>. <span style="background-color:#ffe6e6">In addition, we analysed 19 primary fresh frozen uveal melanomas</span>. <span style="background-color:#ffe0e0">Of the primary tumours, eight were located in the choroid and 11 in both the choroid and ciliary body</span>. <span style="background-color:#ffd9d9">Four of these samples showed a spindle cell type, one an epithelioid cell type and 14 had a mixed population of cells</span>. <span style="background-color:#fff2f2">All samples were derived from tumours with a diameter greater than 12?ml and a prominence greater than 6?ml</span>. <span style="background-color:#fffefe">The research protocol followed the tenets of the Declaration of Helsinki (World Medical Association Declaration of Helsinki 1964; ethical principles for medical research involving human subjects)</span>.</p> 
  </sec> 
  <sec> 
   <h3>Sequencing</h3> 
   <p><span style="background-color:#ffdbdb">DNA was extracted from each cell line using an adaptation of the salting-out method ( Miller et al , 1988 )</span>. <span style="background-color:#ffd3d3">Primers used to amplify parts of the BRAF and RAS genes are given in Table 1 </span></p> 
   <p><span style="background-color:#fffafa">Reactions for BRAF contained 200 ng of DNA, QIAGEN (Hilden, Germany) PCR buffer (10 ? concentrated, containing Tris-Cl, KCl, (NH4)2SO4, 15?m M MgCl2; pH 8.7), Q solution (PCR enhancer), 20?pmol? ? l?1 of each primer, 2?m M of each dNTP and 1.25?U of QIAGEN Taq polymerase</span>. <span style="background-color:#fffefe">Amplification involved 35 cycles of denaturation at 94?C for 45?s, annealing at 56?C for 90?s, and extension at 72?C for 90?s</span>. <span style="background-color:#fffcfc">An initial 12?min denaturation step at 94?C and a final 3?min extension at 72?C were also used</span>. <span style="background-color:#fff5f5">For the RAS genes, DNA was amplified using QIAGEN Taq polymerase as described above, but PCR involved a ?touchdown' thermal cycling routine of two cycles at each annealing temperature, decreasing by steps of 2?C, followed by 25 cycles at the lowest temperature</span>. <span style="background-color:#fffefe">Each cycle consisted of denaturation at 94?C for 45?s, annealing at 65?57?C for 90?s and extension at 72?C for 90?s</span>. <span style="background-color:#fffcfc">An initial 12?min denaturation at 94?C and a final 3?min extension at 72?C were also employed</span>.</p> 
   <p><span style="background-color:#ffcbcb">From 19 fresh frozen uveal melanoma samples, total RNA was extracted with RNeasy kits as described by the manufacturer (QIAGEN)</span>. <span style="background-color:#fffefe">RNA was primed with random primers and reverse transcribed into cDNA in a 20? ? l reaction volume containing 200?U Superscript II (MMV) reverse transcriptase (Invitrogen, Inc., Breda, The Netherlands)</span>. <span style="background-color:#ffc2c2">PCR primers used for amplifying parts of the BRAF and RAS genes in the primary tumour samples are also listed in Table 1 </span>. <span style="background-color:#ffe5e5">A touchdown PCR procedure for BRAF was followed as described above and a fixed annealing temperature of 57?C with a total of 38 cycles was used for the RAS genes followed by a final elongation step of 10?min</span></p> 
   <p><span style="background-color:#fffbfb">PCR products of all samples were electrophoresed through 1.5% TAE/agarose gels stained with ethidium bromide, excised and purified using a QIAGEN QIAquick Gel Extraction Kit</span>. <span style="background-color:#ffe6e6">The RAS and BRAF PCR products were sequenced using Applied Biosystems (ABI) BigDye version 3 reagents according to the manufacturer's instructions using 3.2?pmol? ? l?1 of primer</span>. <span style="background-color:#fffcfc">Sequencing products were precipitated using 75% isopropanol and were run on an ABI 377 automated sequencer (PE Applied Biosystems, Foster City, CA, USA)</span>.</p> 
  </sec> 
  <sec> 
   <h3>Western blot analysis</h3> 
   <p><span style="background-color:#ffe2e2">Protein lysates from the uveal melanoma cell lines were separated on 12.5% SDS?PAGE gels and the proteins transferred to Hybond-polyvinyldifluoride membranes (Amersham biosciences, Buckinghamshire, UK)</span>. <span style="background-color:#ffcbcb">After blocking with 5% skim milk in PBS-Tween solution, the membranes were probed overnight at 4?C with the following primary antibodies specific to each antigen: phospho-MEK1/2 (dilution 1?:?1000), phospho-ERK1/2 (p44/42) (#9106, dilution 1?:?5000), total ERK1/2 (#9102, dilution 1?:?1000) and phospho-ELK1 (dilution 1?:?1000) antibody (all from Cell Signaling Technology, Hertfordshire, UK)</span>. <span style="background-color:#fff7f7">An antibody against actin (Santa Cruz Biotechnology, California, USA) was used as a loading control</span>. <span style="background-color:#fff3f3">Membranes were then incubated with horseradish peroxidase-conjugated IgG anti-mouse, anti-rabbit or anti-goat secondary antibodies for 1?h at room temperature to visualise protein bands</span>.</p> 
  </sec> 
  <sec> 
   <h3>Immunohistochemistry</h3> 
   <p><span style="background-color:#ffd8d8">Acetone-fixed 10? ? m sections of 19 fresh frozen uveal melanomas were washed three times in PBS (pH=7.2) and were incubated with anti-ERK1/2 and anti-phospho-ERK 1/2 antibodies (Cell Signalling Technology, Beverly MA, USA, #9102 and #9106, respectively), both diluted 1?:?100 in PBS with 1% BSA and 2% normal human serum (NHS) at 4?C</span>. <span style="background-color:#fff2f2">The sections were washed three times and incubated with cy3-conjugated AffiniPure goat anti-rabbit IgG or with cy3-conjugated AffiniPure rabbit anti-mouse IgG (Jackson ImmunoResearch, West Grove PA, USA #111-165-003 and #315-165-003) both diluted 1?:?500, respectively, during 1?h at room temperature</span>. <span style="background-color:#fffcfc">Sections were rinsed with PBS three times and incubated for 20?min with Alexa Fluor 647 Phalloidin (Molecular Probes, Leiden, The Netherlands, #A22287) at a 1?:?40 dilution</span>. <span style="background-color:#ffffff">Sections are washed three times with PBS</span>. <span style="background-color:#ffffff">A nuclear staining was preformed by incubating the sections for 5?min with 4?,6-diamidino-2-phenylindole dilacetate (DAPI, Molecular Probes, Leiden, The Netherlands, #D-3571) 1?:?500</span>. <span style="background-color:#fffbfb">Sections were rinsed briefly in PBS and imbedded with Vectashield (Vecta Shield H1000, Brunschwig, Amsterdam, The Netherlands)</span>. <span style="background-color:#fffdfd">For each specimen, the fluorescence of cy3 was determined in three different microscope fields (Leica DMRXA microscope, Leica Microsystems, Rijswijk, The Netherlands)</span>. <span style="background-color:#ffffff">No background fluorescence of cy3 was observed</span>. <span style="background-color:#ffdddd">The number of positively stained tumour cells was estimated for the two antibodies and expressed as the percentage of the total number of tumour cells in the analysed section</span>. <span style="background-color:#ff0000">Percentages were then categorised as either negative &lt;5% (+/?), very weakly positive 5?25% (+), weakly positive 26?50% (++), moderately positive 51?75% (+++) or highly positive 76?100% (++++)</span></p> 
   <p><span style="background-color:#fffcfc">The slides were examined by two observers independently</span>. <span style="background-color:#ffffff">Interobserver disagreement did not exceed one category</span>.</p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>RESULTS</h3> 
  <sec> 
   <h3>Mutation analysis</h3> 
   <p><span style="background-color:#ff9c9c">Of the 11 uveal melanoma cell lines under study, only one cell line (Ocm 1) carried a BRAF mutation, the common V599E (also described by Calipel et al and Kilic et al )</span>. <span style="background-color:#ffdbdb">All primary tumour specimens were wild type for BRAF </span>. <span style="background-color:#ff8383">No mutations were found in the NRAS , HRAS or KRAS genes, in both the cell lines and primary tissue</span></p> 
  </sec> 
  <sec> 
   <h3>Western blotting</h3> 
   <p><span style="background-color:#ff7a7a">In order to assess the level of expression and the activation (by phosphorylation) of members of the MAPK pathway downstream of RAS and BRAF , Western blot analysis was performed on uveal melanoma cell lines ( Table 2A )</span>. <span style="background-color:#ffd1d1">The expression levels of the downstream members of RAS and BRAF are presented in Figure 1 </span>. <span style="background-color:#ffbdbd">In response to the constitutively activating BRAF mutation in Ocm 1, downstream members of the MAPK pathway show activation (phosphorylated MEK, ERK and ELK)</span>. <span style="background-color:#ffc6c6">Levels of expression of the downstream members were not different in the two cell lines derived from the same primary tumour (92.1 and 92.2), except for phosphorylated MEK, indicating that there had been little clonal divergence between the cell populations during in vitro culturing</span>. <span style="background-color:#ffbebe">Interestingly, compared to the phosphorylation status of these members in Ocm 1, most cell lines show activation of MEK, ERK and ELK; however, these cell lines show this activation in the absence of mutations in the upstream RAS and BRAF genes</span>. <span style="background-color:#ff8c8c">The levels of total ERK were remarkably similar across all cell lines, with the exception of two cell lines Mel 285 and Mel 290, which had significantly higher levels of total ERK than the others</span>. <span style="background-color:#fff5f5">In keeping with this observation, these two cell lines also have the highest levels of phosphorylated-ERK</span>. <span style="background-color:#ffb4b4">Figure 2 shows that there is no significant influence of serum on the activity of ERK1/2 in these cell lines, as reported recently by Calipel et al (2003) </span></p> 
  </sec> 
  <sec> 
   <h3>Immunohistochemistry</h3> 
   <p><span style="background-color:#ff8383">Immunofluorescence results of total and phospho-ERK1/2 on a panel of 19 fresh frozen uveal melanoma sections are listed in Table 2 (B) </span>. <span style="background-color:#ffcccc">In seven of the 19 primary tumours, less than 5% of the tumour cells stained positively for ERK1/2 and nine tumours for phosphorylated ERK1/2</span>. <span style="background-color:#ff9292">Despite the lack of mutations in the RAS and BRAF genes in this set of uveal melanomas, it is noteworthy that we observed phosphorylated (active) ERK1/2 expression in 10 of 19 tumours</span>. <span style="background-color:#ffd6d6">There was no significant association between ERK1/2 activation and tumour location or cell type</span>. <span style="background-color:#ffdede">The scoring system for each antibody cannot be compared between antibodies since the antibodies recognise different epitopes and with different affinities; therefore, the staining intensity on Western or by immunohistochemistry is relative only to the other samples for the particular antibody used</span>.</p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>DISCUSSION</h3> 
  <p><span style="background-color:#ff8a8a">In the uveal melanoma cell lines and primary uveal melanomas analysed in our study, only cell line Ocm 1 carried a mutation in BRAF (V599E), thus confirming the documentation of a mutation in this cell line by Calipel et al (2003) and Kilic et al (2004) </span>. <span style="background-color:#fff0f0">Similarly, our observation of a complete lack of BRAF mutations in primary uveal tumours mirrors the findings of several recent reports ( Cohen et al , 2003 ; Cruz et al , 2003 ; Edmunds et al , 2003 ; Rimoldi et al , 2003 ; Weber et al , 2003 ; Kilic et al , 2004 )</span>. <span style="background-color:#ffabab">Table 3 contains a summary of published reports on RAS and BRAF mutations, as well as studies on other members of the MAPK pathway, in uveal melanomas</span>. <span style="background-color:#ffadad">Including the results of our study, to date not a single BRAF mutation has been found in a total of 276 primary or secondary uveal melanoma samples ( Table 3 )</span>. <span style="background-color:#ffb2b2">It is somewhat surprising therefore that three out of three uveal melanoma cell lines studied by Calipel et al (2003) carried the V599E mutation in BRAF , especially since only one out of 11 cell lines in the panel we analysed was found to have this mutation</span>. <span style="background-color:#ffc2c2">Taken together, these data suggest that while a BRAF mutation is not required for uveal melanoma development in vivo , such mutations confer a cellular growth advantage and are hence selected if they occur in cell lines cultured in vitro </span></p> 
  <p><span style="background-color:#ffe4e4">In our study, none of the cell lines or primary tumours carried mutations in any of the three RAS genes (N, H and K), a finding consistent with a previous report ( Soparker et al , 1993 )</span>. <span style="background-color:#ffc6c6">These mutation data are in stark contrast to that for cutaneous melanoma, and would appear to suggest that the MAPK pathway is unlikely to play a significant role in uveal melanoma development</span>. <span style="background-color:#ffbaba">However, on the contrary, by Western blot analysis and immunohistochemistry, we have found substantial evidence for activation of the MAPK pathway, in the absence of serum, in the majority of uveal melanoma samples ? both cell lines and primary uveal melanoma specimens</span>. <span style="background-color:#fff2f2">This frequent MAPK pathway activation in uveal melanoma, independent of RAS and BRAF mutations, has also been reported recently by others ( Rimoldi et al , 2003 ; Weber et al , 2003 ;), but the mechanism is unknown</span>. <span style="background-color:#ffe7e7">Recently, an interaction has been found between the MAPK and the PTEN pathways, both frequently activated in parallel to promote cutaneous melanoma development ( Tsao et al , 2004 )</span>. <span style="background-color:#ffd9d9">It is tempting to speculate that MAPK activation in uveal melanoma may arise via crosstalk with the PI3K/PTEN/AKT pathway, possibly as a consequence of mutation of some of its components (other than PTEN, which is not mutated in this tumour type)</span>. <span style="background-color:#ffc9c9">Thus, mutation analysis of the PI3K and AKT gene families in uveal melanomas seems warranted</span>. <span style="background-color:#ffdada">Interestingly, Graells et al (2004) demonstrated that the proangiogenic vascular endothelial growth factor (VEGF), which is frequently highly expressed in uveal melanoma ( Stitt et al , 1998 ; Sheidow et al , 2000 ), could operate in cutaneous melanoma as a survival factor through increasing MAPK and PI3K pathway activity</span>. <span style="background-color:#ffeaea">It is possible that MAPK activation is such a crucial requirement for uveal melanoma development because it similarly provides survival, and/or antiapoptotic signals, necessary for tumour cell growth and maintenance</span>.</p> 
  <p><span style="background-color:#ffd8d8">Although many uveal melanoma samples have been studied for BRAF and NRAS mutations, few have been analysed for MAPK activation and there is the implicit assumption that this pathway is not involved in uveal melanoma genesis</span>. <span style="background-color:#ffcfcf">Our study is the only study design providing mutation information on all RAS members and expression data on a wide range of participants in the MAPK pathway</span>. <span style="background-color:#ffd0d0">Our data thus support the notion that activation of MAPK is indeed involved in the development of uveal melanoma, but occurs via a different mechanism(s) to that in the majority of cutaneous melanomas</span>. <span style="background-color:#ffe0e0">This conclusion has significant ramifications for the development of rational therapies to treat uveal melanoma as it implies that general inhibitors of the pathway may still be effective even though the tumours do not have mutations of RAS or BRAF .</span></p> 
 </sec> 
 <back> 
  <ack> 
   <p>We thank Dr AD Singh for generously providing a panel of fresh frozen primary uveal melanoma specimens, Dr M Bernsen and P Rombout for the cutaneaous melanoma sections (Department of Pathology, University Medical Centre Nijmegen) and Drs Ksander and Kan-Mitchell for providing some of the cell lines. This work was supported by the National Health and Medical Research Council of Australia, the ?Rotterdamse Vereniging Blindenbelangen' and the ?Landelijke Stichting voor Blinden en Slechtzienden'. FvN is supported by the Netherlands Organisation for Scientific Research and by the Dutch Cancer Society. NG is a recipient of an Aspasia fellowship of the Netherlands Organisation for Scientific Research.</p> 
  </ack> 
  <ref-list> 
   <ref id="bib1"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Alsina 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gorsk 
       </surname> 
       <given-names>
         DH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Germino 
       </surname> 
       <given-names>
         FJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shih 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lu 
       </surname> 
       <given-names>
         SE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         ZG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yang 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hait 
       </surname> 
       <given-names>
         WN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Goydos 
       </surname> 
       <given-names>
         JS 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       6419 
     </fpage> 
     <lpage>
       6425 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||9|6419||bib1|'--> 
     <pub-id pub-id-type="pmid">
       14695143 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib2"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Brose 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Volpe 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Feldman 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kumar 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rishi 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gerrero 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Einhorn 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Herlyn 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Minna 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nicholson 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Roth 
       </surname> 
       <given-names>
         JA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Albelda 
       </surname> 
       <given-names>
         SM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Davies 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cox 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Brignell 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stephens 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Futreal 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wooster 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stratton 
       </surname> 
       <given-names>
         MR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weber 
       </surname> 
       <given-names>
         BL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       BRAF and RAS mutations in human lung cancer and melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2002 
     </year> 
     <volume>
       62 
     </volume> 
     <fpage>
       6997 
     </fpage> 
     <lpage>
       7000 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||62|6997||bib2|'--> 
     <pub-id pub-id-type="pmid">
       12460918 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib3"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Calipel 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lefevre 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pouponnot 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mouriaux 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Eychene 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mascarelli 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway 
     </article-h3> 
     <source />J Biol Chem 
     <year>
       2003 
     </year> 
     <volume>
       278 
     </volume> 
     <fpage>
       42409 
     </fpage> 
     <lpage>
       42418 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1074/jbcM308709200 
     </pub-id>doi: 
     <!--PubMed citation query: 'J Biol Chem||278|42409||bib3|'--> 
     <pub-id pub-id-type="pmid">
       12917419 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib4"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cohen 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Goldenberg-Cohen 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parrella 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chowers 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Merbs 
       </surname> 
       <given-names>
         SL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pe'er 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sidransky 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Lack of BRAF mutation in primary uveal melanoma 
     </article-h3> 
     <source />Invest Ophthalmol Vis Sci 
     <year>
       2003 
     </year> 
     <volume>
       44 
     </volume> 
     <fpage>
       2876 
     </fpage> 
     <lpage>
       2878 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1167/iovs.02-1329 
     </pub-id>doi: 
     <!--PubMed citation query: 'Invest Ophthalmol Vis Sci||44|2876||bib4|'--> 
     <pub-id pub-id-type="pmid">
       12824225 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib5"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cohen 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rosenbaum 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Begum 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Goldenberg 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Esche 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lavie 
       </surname> 
       <given-names>
         O 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sidransky 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Westra 
       </surname> 
       <given-names>
         WH 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2004 
     </year> 
     <volume>
       10 
     </volume> 
     <fpage>
       3444 
     </fpage> 
     <lpage>
       3447 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||10|3444||bib5|'--> 
     <pub-id pub-id-type="pmid">
       15161700 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib6"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cohen 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zavala-Pompa 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sequeira 
       </surname> 
       <given-names>
         JH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shoji 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sexton 
       </surname> 
       <given-names>
         DG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cotsonis 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cerimele 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Govindarajan 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Macaron 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Arbister 
       </surname> 
       <given-names>
         JL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mitogen-activated protein kinase activation is an early event in melanoma progression 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2002 
     </year> 
     <volume>
       8 
     </volume> 
     <fpage>
       3728 
     </fpage> 
     <lpage>
       3733 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||8|3728||bib6|'--> 
     <pub-id pub-id-type="pmid">
       12473582 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib7"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cruz 
       </surname> 
       <given-names>
         F 
       </given-names> 
       <suffix>
         III 
       </suffix> 
      </name> 
      <name> 
       <surname>
         Rubin 
       </surname> 
       <given-names>
         BP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wilson 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Town 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schroeder 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haley 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bainbridge 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heinrich 
       </surname> 
       <given-names>
         MC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Corless 
       </surname> 
       <given-names>
         CL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Absence of BRAF and NRAS mutations in uveal melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <supplement>
       18 
     </supplement> 
     <fpage>
       5761 
     </fpage> 
     <lpage>
       5766 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|5761||bib7|'--> 
     <pub-id pub-id-type="pmid">
       14522897 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib8"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Davies 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bignell 
       </surname> 
       <given-names>
         GR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cox 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stephens 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Edkins 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Clegg 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Teague 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Woffendin 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Garnett 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bottomley 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Davis 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dicks 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ewing 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Floyd 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gray 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hall 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hawes 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hughes 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kosmidou 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Menzies 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mould 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parker 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stevens 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Watt 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hooper 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wilson 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jayatilake 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gusterson 
       </surname> 
       <given-names>
         BA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cooper 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shipley 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hargrave 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pritchard-Jones 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Maitland 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chenevix-Trench 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Riggins 
       </surname> 
       <given-names>
         GJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bigner 
       </surname> 
       <given-names>
         DD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Palmieri 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cossu 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Flanagan 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nicholson 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ho 
       </surname> 
       <given-names>
         JW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Leung 
       </surname> 
       <given-names>
         SY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yuen 
       </surname> 
       <given-names>
         ST 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weber 
       </surname> 
       <given-names>
         BL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Seigler 
       </surname> 
       <given-names>
         HF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Darrow 
       </surname> 
       <given-names>
         TL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Paterson 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marais 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marshall 
       </surname> 
       <given-names>
         CJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wooster 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stratton 
       </surname> 
       <given-names>
         MR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Futreal 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutations of the BRAF gene in human cancer 
     </article-h3> 
     <source />Nature 
     <year>
       2002 
     </year> 
     <volume>
       417 
     </volume> 
     <fpage>
       949 
     </fpage> 
     <lpage>
       954 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1038/nature00766 
     </pub-id>doi: 
     <!--PubMed citation query: 'Nature||417|949||bib8|'--> 
     <pub-id pub-id-type="pmid">
       12068308 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib9"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         de Waard-Siebinga 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Blom 
       </surname> 
       <given-names>
         DJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Griffioen 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schrier 
       </surname> 
       <given-names>
         PI 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hoogendoorn 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Beverstock 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Danen 
       </surname> 
       <given-names>
         EH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jager 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Establishment and characterization of an uveal-melanoma cell line 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       1995 
     </year> 
     <volume>
       62 
     </volume> 
     <fpage>
       155 
     </fpage> 
     <lpage>
       161 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||62|155||bib9|'--> 
     <pub-id pub-id-type="pmid">
       7622289 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib10"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Diener-West 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hawkins 
       </surname> 
       <given-names>
         BS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Markowitz 
       </surname> 
       <given-names>
         JA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schachat 
       </surname> 
       <given-names>
         AP 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988 
     </article-h3> 
     <source />Arch Ophthalmol 
     <year>
       1992 
     </year> 
     <volume>
       110 
     </volume> 
     <fpage>
       245 
     </fpage> 
     <lpage>
       250 
     </lpage> 
     <!--PubMed citation query: 'Arch Ophthalmol||110|245||bib10|'--> 
     <pub-id pub-id-type="pmid">
       1531290 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib11"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Dong 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Phelps 
       </surname> 
       <given-names>
         RG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Qiao 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yao 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Benard 
       </surname> 
       <given-names>
         O 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ronai 
       </surname> 
       <given-names>
         Z 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Aaronson 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <supplement>
       14 
     </supplement> 
     <fpage>
       3883 
     </fpage> 
     <lpage>
       3885 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|3883||bib11|'--> 
     <pub-id pub-id-type="pmid">
       12873977 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib12"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Edmunds 
       </surname> 
       <given-names>
         SC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cree 
       </surname> 
       <given-names>
         IA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Di Nicolantonio 
       </surname> 
       <given-names>
         F 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hungerford 
       </surname> 
       <given-names>
         JL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hurren 
       </surname> 
       <given-names>
         JS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kelsell 
       </surname> 
       <given-names>
         DP 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas 
     </article-h3> 
     <source />Br J Cancer 
     <year>
       2003 
     </year> 
     <volume>
       88 
     </volume> 
     <fpage>
       1403 
     </fpage> 
     <lpage>
       1405 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1038/sj.bjc.6600919 
     </pub-id>doi: 
     <!--PubMed citation query: 'Br J Cancer||88|1403||bib12|'--> 
     <pub-id pub-id-type="pmid">
       12778069 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib13"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Gorden 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Osman 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gai 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         He 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Huang 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Davidson 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Houghton 
       </surname> 
       <given-names>
         AN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Busam 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Polsky 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <supplement>
       14 
     </supplement> 
     <fpage>
       3955 
     </fpage> 
     <lpage>
       3957 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|3955||bib13|'--> 
     <pub-id pub-id-type="pmid">
       12873990 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib14"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Graells 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vinyals 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Figueras 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Llorens 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Moreno 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marcoval 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gonzalez 
       </surname> 
       <given-names>
         FJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fabra 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling 
     </article-h3> 
     <source />J Invest Dermatol 
     <year>
       2004 
     </year> 
     <volume>
       123 
     </volume> 
     <fpage>
       1151 
     </fpage> 
     <lpage>
       1161 
     </lpage> 
     <!--PubMed citation query: 'J Invest Dermatol||123|1151||bib14|'--> 
     <pub-id pub-id-type="pmid">
       15610528 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib15"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Guldberg 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         thor Straten 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Birck 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ahrenkiel 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kirkin 
       </surname> 
       <given-names>
         AF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zeuthen 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       1997 
     </year> 
     <volume>
       57 
     </volume> 
     <fpage>
       3660 
     </fpage> 
     <lpage>
       3663 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||57|3660||bib15|'--> 
     <pub-id pub-id-type="pmid">
       9288767 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib16"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kan-Mitchell 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mitchell 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rao 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liggett 
       </surname> 
       <given-names>
         PE 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes 
     </article-h3> 
     <source />Invest Ophthalmol Vis Sci 
     <year>
       1989 
     </year> 
     <volume>
       30 
     </volume> 
     <fpage>
       829 
     </fpage> 
     <lpage>
       834 
     </lpage> 
     <!--PubMed citation query: 'Invest Ophthalmol Vis Sci||30|829||bib16|'--> 
     <pub-id pub-id-type="pmid">
       2722439 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib17"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kilic 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bruggenwirth 
       </surname> 
       <given-names>
         HT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Verbiest 
       </surname> 
       <given-names>
         MM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zwarthoff 
       </surname> 
       <given-names>
         EC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mooy 
       </surname> 
       <given-names>
         NM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Luyten 
       </surname> 
       <given-names>
         GP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         De Klein 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       The RAS-BRAF kinase pathway is not involved in uveal melanoma 
     </article-h3> 
     <source />Melanoma Res 
     <year>
       2004 
     </year> 
     <volume>
       14 
     </volume> 
     <fpage>
       203 
     </fpage> 
     <lpage>
       205 
     </lpage> 
     <!--PubMed citation query: 'Melanoma Res||14|203||bib17|'--> 
     <pub-id pub-id-type="pmid">
       15179189 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib18"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kumar 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Angelini 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Czene 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sauroja 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hahka-Kemppinen 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pyrhonen 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hemminki 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       BRAF mutations in metastatic melanoma: a possible association with clinical outcome 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2003a 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       3362 
     </fpage> 
     <lpage>
       3368 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||9|3362||bib18|'--> 
     <pub-id pub-id-type="pmid">
       12960123 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib19"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kumar 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Angelini 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hemminki 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9 
     </article-h3> 
     <source />Oncogene 
     <year>
       2003b 
     </year> 
     <volume>
       22 
     </volume> 
     <fpage>
       9217 
     </fpage> 
     <lpage>
       9224 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1038/sj.onc.1206909 
     </pub-id>doi: 
     <!--PubMed citation query: 'Oncogene||22|9217||bib19|'--> 
     <pub-id pub-id-type="pmid">
       14681681 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib20"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Luyten 
       </surname> 
       <given-names>
         GP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Naus 
       </surname> 
       <given-names>
         NC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mooy 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hagemeijer 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kan-Mitchell 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         van Drunen 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vuzevski 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         de Jong 
       </surname> 
       <given-names>
         PT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Luider 
       </surname> 
       <given-names>
         TM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Establishment and characterization of primary and metastatic uveal melanoma cell lines 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       1996 
     </year> 
     <volume>
       66 
     </volume> 
     <fpage>
       380 
     </fpage> 
     <lpage>
       387 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1002/(sici)1097-0215 
     </pub-id>doi: 
     <!--PubMed citation query: 'Int J Cancer||66|380||bib20|'--> 
     <pub-id pub-id-type="pmid">
       8621261 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib21"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Maldonado 
       </surname> 
       <given-names>
         JL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fridlyand 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Patel 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jain 
       </surname> 
       <given-names>
         AN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Busam 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kageshita 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ono 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Albertson 
       </surname> 
       <given-names>
         DG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pinkel 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bastian 
       </surname> 
       <given-names>
         BC 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Determinants of BRAF mutations in primary melanomas 
     </article-h3> 
     <source />J Natl Cancer Inst 
     <year>
       2003 
     </year> 
     <volume>
       95 
     </volume> 
     <fpage>
       1878 
     </fpage> 
     <lpage>
       1890 
     </lpage> 
     <!--PubMed citation query: 'J Natl Cancer Inst||95|1878||bib21|'--> 
     <pub-id pub-id-type="pmid">
       14679157 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib22"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Miller 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dykes 
       </surname> 
       <given-names>
         DD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Polesky 
       </surname> 
       <given-names>
         HF 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A simple salting out procedure for extracting DNA from human nucleated cells 
     </article-h3> 
     <source />Nucl Acids Res 
     <year>
       1988 
     </year> 
     <volume>
       16 
     </volume> 
     <fpage>
       1215 
     </fpage> 
     <!--PubMed citation query: 'Nucl Acids Res||16|1215||bib22|'--> 
    </citation> 
   </ref> 
   <ref id="bib23"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Mooy 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         de Jong 
       </surname> 
       <given-names>
         PT 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Prognostic parameters in uveal melanoma: a review 
     </article-h3> 
     <source />Surv Ophthalmol 
     <year>
       1996 
     </year> 
     <volume>
       41 
     </volume> 
     <fpage>
       215 
     </fpage> 
     <lpage>
       228 
     </lpage> 
     <!--PubMed citation query: 'Surv Ophthalmol||41|215||bib23|'--> 
     <pub-id pub-id-type="pmid">
       8970236 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib24"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Mooy 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Van der Helm 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Van der Kwast 
       </surname> 
       <given-names>
         TH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         De Jong 
       </surname> 
       <given-names>
         PT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ruiter 
       </surname> 
       <given-names>
         DJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zwarthoff 
       </surname> 
       <given-names>
         EC 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited 
     </article-h3> 
     <source />Br J Cancer 
     <year>
       1991 
     </year> 
     <volume>
       64 
     </volume> 
     <fpage>
       411 
     </fpage> 
     <lpage>
       413 
     </lpage> 
     <!--PubMed citation query: 'Br J Cancer||64|411||bib24|'--> 
     <pub-id pub-id-type="pmid">
       1892776 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib25"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Naus 
       </surname> 
       <given-names>
         NC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zuidervaart 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rayman 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Slater 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         van Drunen 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ksander 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Luyten 
       </surname> 
       <given-names>
         GP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Klein 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutation analysis of the PTEN gene in uveal melanoma cell lines 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       2000 
     </year> 
     <volume>
       87 
     </volume> 
     <fpage>
       151 
     </fpage> 
     <lpage>
       153 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||87|151||bib25|'--> 
     <pub-id pub-id-type="pmid">
       10861467 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib26"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Omholt 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Platz 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kanter 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ringborg 
       </surname> 
       <given-names>
         U 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hansson 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       6483 
     </fpage> 
     <lpage>
       6488 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||9|6483||bib26|'--> 
     <pub-id pub-id-type="pmid">
       14695152 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib27"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Pollock 
       </surname> 
       <given-names>
         PM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Harper 
       </surname> 
       <given-names>
         UL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hansen 
       </surname> 
       <given-names>
         KS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yudt 
       </surname> 
       <given-names>
         LM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stark 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Robbins 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Moses 
       </surname> 
       <given-names>
         TY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hostetter 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wagner 
       </surname> 
       <given-names>
         U 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kakareka 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Salem 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pohida 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heenan 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Duray 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kallioniemi 
       </surname> 
       <given-names>
         O 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hayward 
       </surname> 
       <given-names>
         NK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Trent 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Meltzer 
       </surname> 
       <given-names>
         PS 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       High frequency of BRAF mutations in nevi 
     </article-h3> 
     <source />Nat Genet 
     <year>
       2003 
     </year> 
     <volume>
       33 
     </volume> 
     <fpage>
       19 
     </fpage> 
     <lpage>
       20 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1038/ng1054 
     </pub-id>doi: 
     <!--PubMed citation query: 'Nat Genet||33|19||bib27|'--> 
     <pub-id pub-id-type="pmid">
       12447372 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib28"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Reifenberger 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Knobbe 
       </surname> 
       <given-names>
         CB 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sterzinger 
       </surname> 
       <given-names>
         AA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Blaschke 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schulte 
       </surname> 
       <given-names>
         KW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ruzicka 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Reifenberger 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       2004 
     </year> 
     <volume>
       109 
     </volume> 
     <fpage>
       377 
     </fpage> 
     <lpage>
       384 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1002/ijc.11722 
     </pub-id>doi: 
     <!--PubMed citation query: 'Int J Cancer||109|377||bib28|'--> 
     <pub-id pub-id-type="pmid">
       14961576 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib29"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Rimoldi 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Salvi 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lienard 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lejeune 
       </surname> 
       <given-names>
         FJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Speiser 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zografos 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cerottini 
       </surname> 
       <given-names>
         JC 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Lack of BRAF mutations in uveal melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <fpage>
       5712 
     </fpage> 
     <lpage>
       5715 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|5712||bib29|'--> 
     <pub-id pub-id-type="pmid">
       14522889 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib30"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Satyamoorthy 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Li 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gerrero 
       </surname> 
       <given-names>
         MR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Brose 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Volpe 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weber 
       </surname> 
       <given-names>
         BL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Van Belle 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Elder 
       </surname> 
       <given-names>
         DE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Herlyn 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <fpage>
       756 
     </fpage> 
     <lpage>
       759 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|756||bib30|'--> 
     <pub-id pub-id-type="pmid">
       12591721 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib31"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Scott 
       </surname> 
       <given-names>
         RJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vajdic 
       </surname> 
       <given-names>
         CM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Armstrong 
       </surname> 
       <given-names>
         BK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ainsworth 
       </surname> 
       <given-names>
         CJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Meldrum 
       </surname> 
       <given-names>
         CJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Aitken 
       </surname> 
       <given-names>
         JF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kricker 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       BRCA2 mutations in a population-based series of patients with ocular melanoma 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       2002 
     </year> 
     <volume>
       102 
     </volume> 
     <fpage>
       188 
     </fpage> 
     <lpage>
       191 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1002/ijc.10693 
     </pub-id>doi: 
     <!--PubMed citation query: 'Int J Cancer||102|188||bib31|'--> 
     <pub-id pub-id-type="pmid">
       12385017 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib32"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Sheidow 
       </surname> 
       <given-names>
         TG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hooper 
       </surname> 
       <given-names>
         PL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Crukley 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Young 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Heathcote 
       </surname> 
       <given-names>
         JG 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis 
     </article-h3> 
     <source />Br J Ophthalmol 
     <year>
       2000 
     </year> 
     <volume>
       84 
     </volume> 
     <fpage>
       750 
     </fpage> 
     <lpage>
       756 
     </lpage> 
     <!--PubMed citation query: 'Br J Ophthalmol||84|750||bib32|'--> 
     <pub-id pub-id-type="pmid">
       10873988 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib33"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Shinozaki 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fujimoto 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Morton 
       </surname> 
       <given-names>
         DL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hoon 
       </surname> 
       <given-names>
         DS 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas 
     </article-h3> 
     <source />Clin Cancer Res 
     <year>
       2004 
     </year> 
     <volume>
       10 
     </volume> 
     <fpage>
       1753 
     </fpage> 
     <lpage>
       1757 
     </lpage> 
     <!--PubMed citation query: 'Clin Cancer Res||10|1753||bib33|'--> 
     <pub-id pub-id-type="pmid">
       15014028 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib34"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Sisley 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rennie 
       </surname> 
       <given-names>
         IG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parsons 
       </surname> 
       <given-names>
         MA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jacques 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hammond 
       </surname> 
       <given-names>
         DW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bell 
       </surname> 
       <given-names>
         SM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Potter 
       </surname> 
       <given-names>
         AM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rees 
       </surname> 
       <given-names>
         RC 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis 
     </article-h3> 
     <source />Genes Chromosomes Cancer 
     <year>
       1997 
     </year> 
     <volume>
       19 
     </volume> 
     <fpage>
       22 
     </fpage> 
     <lpage>
       28 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1002/(sici)1098-2264(199705) 
     </pub-id>doi: 
     <!--PubMed citation query: 'Genes Chromosomes Cancer||19|22||bib34|'--> 
     <pub-id pub-id-type="pmid">
       9135991 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib35"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Soparker 
       </surname> 
       <given-names>
         CN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         O'Brien 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Albert 
       </surname> 
       <given-names>
         DM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Investigation of the role of the ras protooncogene point mutation in human uveal melanomas 
     </article-h3> 
     <source />Invest Ophthalmol Vis Sci 
     <year>
       1993 
     </year> 
     <volume>
       34 
     </volume> 
     <fpage>
       2203 
     </fpage> 
     <lpage>
       2209 
     </lpage> 
     <!--PubMed citation query: 'Invest Ophthalmol Vis Sci||34|2203||bib35|'--> 
     <pub-id pub-id-type="pmid">
       8505202 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib36"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Stahl 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cheung 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sharma 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Trivedi 
       </surname> 
       <given-names>
         NR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shanmugam 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Robertson 
       </surname> 
       <given-names>
         GP 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Loss of PTEN promotes tumor development in malignant melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2003 
     </year> 
     <volume>
       63 
     </volume> 
     <fpage>
       2881 
     </fpage> 
     <lpage>
       2890 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||63|2881||bib36|'--> 
     <pub-id pub-id-type="pmid">
       12782594 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib37"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Stitt 
       </surname> 
       <given-names>
         AW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Simpson 
       </surname> 
       <given-names>
         DA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Boocock 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gardiner 
       </surname> 
       <given-names>
         TA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Murphy 
       </surname> 
       <given-names>
         GM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Archer 
       </surname> 
       <given-names>
         DB 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours 
     </article-h3> 
     <source />J Pathol 
     <year>
       1998 
     </year> 
     <volume>
       186 
     </volume> 
     <fpage>
       306 
     </fpage> 
     <lpage>
       312 
     </lpage> 
     <!--PubMed citation query: 'J Pathol||186|306||bib37|'--> 
     <pub-id pub-id-type="pmid">
       10211121 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib38"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Tsao 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Goel 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wu 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yang 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Haluska 
       </surname> 
       <given-names>
         FG 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma 
     </article-h3> 
     <source />J Invest Dermatol 
     <year>
       2004 
     </year> 
     <volume>
       122 
     </volume> 
     <fpage>
       337 
     </fpage> 
     <lpage>
       341 
     </lpage> 
     <!--PubMed citation query: 'J Invest Dermatol||122|337||bib38|'--> 
     <pub-id pub-id-type="pmid">
       15009714 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib39"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Uribe 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wistuba 
       </surname> 
       <given-names>
         II 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gonzalez 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin 
     </article-h3> 
     <source />Am J Dermatopathol 
     <year>
       2003 
     </year> 
     <volume>
       25 
     </volume> 
     <fpage>
       365 
     </fpage> 
     <lpage>
       370 
     </lpage> 
     <!--PubMed citation query: 'Am J Dermatopathol||25|365||bib39|'--> 
     <pub-id pub-id-type="pmid">
       14501284 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib40"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         van der Velden 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Metzelaar-Blok 
       </surname> 
       <given-names>
         JA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bergman 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hurks 
       </surname> 
       <given-names>
         HMH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Frants 
       </surname> 
       <given-names>
         RR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gruis 
       </surname> 
       <given-names>
         NA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jager 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2001 
     </year> 
     <volume>
       61 
     </volume> 
     <fpage>
       5303 
     </fpage> 
     <lpage>
       5306 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||61|5303||bib40|'--> 
     <pub-id pub-id-type="pmid">
       11431374 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib41"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         van Elsas 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zerp 
       </surname> 
       <given-names>
         SF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         van der Flier 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kruse 
       </surname> 
       <given-names>
         KM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Aarnoudse 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hayward 
       </surname> 
       <given-names>
         NK 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ruiter 
       </surname> 
       <given-names>
         DJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schrier 
       </surname> 
       <given-names>
         PI 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma 
     </article-h3> 
     <source />Am J Pathol 
     <year>
       1996 
     </year> 
     <volume>
       149 
     </volume> 
     <fpage>
       883 
     </fpage> 
     <lpage>
       893 
     </lpage> 
     <!--PubMed citation query: 'Am J Pathol||149|883||bib41|'--> 
     <pub-id pub-id-type="pmid">
       8780392 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib42"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Weber 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hengge 
       </surname> 
       <given-names>
         UR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Urbanik 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Markwart 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mirmohammadsaegh 
       </surname> 
      </name> 
      <name> 
       <surname>
         Reichel 
       </surname> 
       <given-names>
         MB 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wittekind 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wiedemann 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tannapfel 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Absence of mutations of the BRAF gene and constitutive activation of extracellulr-regulated kinase in malignant melanomas of the uvea 
     </article-h3> 
     <source />Lab Invest 
     <year>
       2003 
     </year> 
     <volume>
       83 
     </volume> 
     <fpage>
       1771 
     </fpage> 
     <lpage>
       1776 
     </lpage> 
     <pub-id pub-id-type="doi">
       10.1097/01.LAB.0000101732.89463.29 
     </pub-id>doi: 
     <!--PubMed citation query: 'Lab Invest||83|1771||bib42|'--> 
     <pub-id pub-id-type="pmid">
       14691295 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib43"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Yazdi 
       </surname> 
       <given-names>
         AS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Palmedo 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Flaig 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kutzner 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sander 
       </surname> 
       <given-names>
         CA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       SP-11 different frequencies of a BRAF point mutation in melanocytic skin lesions 
     </article-h3> 
     <source />Pigment Cell Res 
     <year>
       2003 
     </year> 
     <volume>
       16 
     </volume> 
     <fpage>
       580 
     </fpage> 
     <!--PubMed citation query: 'Pigment Cell Res||16|580||bib43|'--> 
    </citation> 
   </ref> 
  </ref-list> 
 </back> 
 <floats-wrap> 
  <fig id="fig1"> 
   <label>Figure 1</label> 
   <p>Expression levels of members of the MAPK pathway downstream of RAS and BRAF in 11 uveal melanoma cell lines. Actin levels were assessed as a loading control.</p> 
   <graphic mime-subtype="jpeg" xlink:href="92-6602598f1"></graphic> 
  </fig> 
  <fig id="fig2"> 
   <label>Figure 2</label> 
   <p>ERK1/2 and phospho-ERK1/2 expression in uveal melanoma cell lines (Mel 202, Ocm 1, Mel 285, Mel 290) cultured with (+) and without (?) serum (24?h). A similar lack of effect of serum on influencing the level of phospho-ERK1/2 was seen for each of the other uveal melanoma cell lines (data not shown).</p> 
   <graphic mime-subtype="jpeg" xlink:href="92-6602598f2"></graphic> 
  </fig> 
  <table-wrap id="tbl1" position="float"> 
   <label>Table 1</label> 
   <p content-type="table-h3">PCR primers for 
    <italic>
      BRAF 
    </italic>, 
    <italic>
      NRAS 
    </italic>, 
    <italic>
      KRAS 
    </italic> and 
    <italic>
      HRAS 
    </italic> genes</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Samples 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Gene 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Exon/region 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Primer name 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Primer sequence (5?&gt;3?) 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Product size (bp) 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">Cell lines</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         BRAF 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">11</td> 
      <td align="center" charoff="50" valign="top">x11F</td> 
      <td align="left" charoff="50" valign="top">CTCTCAGGCATAAGGTAATGTAC</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">(DNA)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">x11R</td> 
      <td align="left" charoff="50" valign="top">GAGTCCCGACTGCTGTGAAC</td> 
      <td align="center" charoff="50" valign="top">360</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         BRAF 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">15</td> 
      <td align="center" charoff="50" valign="top">x15F</td> 
      <td align="left" charoff="50" valign="top">CTAAGAGGAAAGATGAAGTACTATG</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">x15R</td> 
      <td align="left" charoff="50" valign="top">CTAGTAACTCAGCAGCATCTCAG</td> 
      <td align="center" charoff="50" valign="top">328</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         NRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">1</td> 
      <td align="center" charoff="50" valign="top">X1F</td> 
      <td align="left" charoff="50" valign="top">CTGGTTTCCAACAGGTTCTTG</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">X1R</td> 
      <td align="left" charoff="50" valign="top">TGCTACTCCAATCATCTGGTC</td> 
      <td align="center" charoff="50" valign="top">567</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         NRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">2</td> 
      <td align="center" charoff="50" valign="top">X2F</td> 
      <td align="left" charoff="50" valign="top">CACACCCCCAGGATTCTTAC</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">X2R</td> 
      <td align="left" charoff="50" valign="top">GTTCCAAGTCATTCCCAGTAG</td> 
      <td align="center" charoff="50" valign="top">438</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         HRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">1</td> 
      <td align="center" charoff="50" valign="top">X1F</td> 
      <td align="left" charoff="50" valign="top">GGCAGGAGACCCTGTAGGA</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">X1R</td> 
      <td align="left" charoff="50" valign="top">AGCCCTATCCTGGCTGTGT</td> 
      <td align="center" charoff="50" valign="top">232</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         HRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">2</td> 
      <td align="center" charoff="50" valign="top">X2F</td> 
      <td align="left" charoff="50" valign="top">AGAGGCTGGCTGTGTGAACT</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">X2R</td> 
      <td align="left" charoff="50" valign="top">ACATGCGCAGAGAGAGGACAG</td> 
      <td align="center" charoff="50" valign="top">344</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         KRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">1</td> 
      <td align="center" charoff="50" valign="top">X1F</td> 
      <td align="left" charoff="50" valign="top">GATTTTCCTAGGCGGCGG</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">X1R</td> 
      <td align="left" charoff="50" valign="top">GTCCGCTCCGTACCTCTCTC</td> 
      <td align="center" charoff="50" valign="top">199</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         KRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">2</td> 
      <td align="center" charoff="50" valign="top">X2F</td> 
      <td align="left" charoff="50" valign="top">GGCCTGCTGAAAATGACTG</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">X2R</td> 
      <td align="left" charoff="50" valign="top">TATTGTTGGATCATATTCGTCCAC</td> 
      <td align="center" charoff="50" valign="top">120</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Tumours</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         BRAF 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">11?15</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">TCAACCACAGGTTTGTCTGC</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">(cDNA)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">R</td> 
      <td align="left" charoff="50" valign="top">GATGACTTCTGGTGCCATCC</td> 
      <td align="center" charoff="50" valign="top">696</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         NRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">GGGGTCTCCAACATTTTTCC</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">R</td> 
      <td align="left" charoff="50" valign="top">TCGCTTAATCTGCTCCCTGT</td> 
      <td align="center" charoff="50" valign="top">390</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         HRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">CAGGAGACCCTGTAGGAGGA</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">R</td> 
      <td align="left" charoff="50" valign="top">TTTACTGTGATCCCATCTGTGC</td> 
      <td align="center" charoff="50" valign="top">968</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         KRAS 
       </italic> </td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">F</td> 
      <td align="left" charoff="50" valign="top">AGGCCTGCTGAAAATGACTG</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">R</td> 
      <td align="left" charoff="50" valign="top">TTCAATCTGTATTGTCGGATCTC</td> 
      <td align="center" charoff="50" valign="top">519</td> 
     </tr> 
    </tbody> 
   </table> 
  </table-wrap> 
  <table-wrap id="tbl2" position="float"> 
   <label>Table 2</label> 
   <p content-type="table-h3">Summary of mutation analyses, immunohistochemical and Western blotting data in uveal melanoma cell lines and primary uveal melanomas</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" colspan="9" valign="top">(A) Uveal melanoma cell lines 
       <hr /> </th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Cell line 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          BRAF 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          NRAS 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          KRAS 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          HRAS 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Total ERK Western 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Phospho-ERK Western 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Phospho-MEK Western 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Phospho-ELK Western 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" colspan="9" valign="top"> 
       <bold> 
        <italic>
          From primaries 
        </italic> 
       </bold> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Ocm 1</td> 
      <td align="center" charoff="50" valign="top">V599E</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Mel 285</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Mel 290</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">92.1</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">92.2</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Ocm 3</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Mel 202</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Mel 270</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="9" valign="top"> 
       <bold> 
        <italic>
          From metastases 
        </italic> 
       </bold> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Omm 1.3</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Omm 1.5</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Omm 1</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="9" valign="top">(B) Primary uveal melanomas</td> 
     </tr> 
    </tbody> 
   </table> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Tumour sample ID 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          BRAF 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          NRAS 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          KRAS 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          HRAS 
        </italic> mutation analysis 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Total ERK1/2 IHC 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Phospho ERK1/2 IHC 
       </bold> </th> 
      <th align="center" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 1</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 2</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 3</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 4</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 5</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 6</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 7</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 8</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 9</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">10</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">11</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">12</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">13</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">14</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">15</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">16</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">17</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">18</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">19</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">WT</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">+</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Positive control cutaneous melanoma</td> 
      <td align="center" charoff="50" valign="top">V599E</td> 
      <td align="center" charoff="50" valign="top">NA</td> 
      <td align="center" charoff="50" valign="top">NA</td> 
      <td align="center" charoff="50" valign="top">NA</td> 
      <td align="center" charoff="50" valign="top">+++</td> 
      <td align="center" charoff="50" valign="top">++++</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote1"> 
     <label></label> 
     <p>The level of expression of the Western blotting and immunhistochemistry (IHC) experiments were scored and categorised as either negative (?), weakly positive (+), weak?moderately positive (++), moderately positive (+++) or strongly positive (++++).</p> 
    </fn> 
    <fn id="tbfnote2"> 
     <label></label> 
     <p>NA=not applicable.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
  <table-wrap id="tbl3" position="float"> 
   <label>Table 3</label> 
   <p content-type="table-h3">Summary of published 
    <italic>
      RAS 
    </italic> and 
    <italic>
      BRAF 
    </italic> mutation studies in ocular melanoma</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="left" /> 
     <col align="left" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Study 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Sample type 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          BRAF 
        </italic> mutation frequency 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold> 
        <italic>
          NRAS 
        </italic> mutation frequency 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold> 
        <italic>
          KRAS 
        </italic> mutation frequency 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold> 
        <italic>
          HRAS 
        </italic> mutation frequency 
       </bold> </th> 
      <th align="left" charoff="50" valign="top"> 
       <bold>
         Activation of other MAPK members 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib24">
         Mooy 
        <italic>
          et al 
        </italic> (1991) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">Codons 12,13,61 (0/29)</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib35">
         Soparker 
        <italic>
          et al 
        </italic> (1993) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">Exon 1 (0/33)</td> 
      <td align="left" charoff="50" valign="top">Exon 1 (0/36)</td> 
      <td align="left" charoff="50" valign="top">0/23</td> 
      <td align="left" charoff="50" valign="top">?</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">Exon 2 (0/39)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib12">
         Edmunds 
        <italic>
          et al 
        </italic> (2003) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">0/48</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib4">
         Cohen 
        <italic>
          et al 
        </italic> (2003) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">0/29</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib29">
         Rimoldi 
        <italic>
          et al 
        </italic> (2003) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">0/10</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">Expression of MEK/ERK</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">2? tumours</td> 
      <td align="center" charoff="50" valign="top">0/30</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib42">
         Weber 
        <italic>
          et al 
        </italic> (2003) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">0/42</td> 
      <td align="left" charoff="50" valign="top">0/42</td> 
      <td align="left" charoff="50" valign="top">0/42</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">Phospho-ERK (36/42) baseline expression ERK (42/42)</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">2? tumours</td> 
      <td align="center" charoff="50" valign="top">0/3</td> 
      <td align="left" charoff="50" valign="top">0/3</td> 
      <td align="left" charoff="50" valign="top">0/3</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Cruz 
       <italic>
         et al 
       </italic> (Cancer Res.)</td> 
      <td align="left" charoff="50" valign="top">Tumours<sup>a</sup></td> 
      <td align="center" charoff="50" valign="top">0/62</td> 
      <td align="left" charoff="50" valign="top">Exon 1 (0/22)</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">Exon 2 (0/47)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib3">
         Calipel 
        <italic>
          et al 
        </italic> (2003) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">Cell lines</td> 
      <td align="center" charoff="50" valign="top">3/3<sup>b</sup></td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">High MEK/ERK levels</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top"> 
       <xref ref-type="other" rid="bib17">
         Kilic 
        <italic>
          et al 
        </italic> (2004) 
       </xref> </td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">0/33</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">?</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">Cell lines</td> 
      <td align="center" charoff="50" valign="top">1/11</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">This study</td> 
      <td align="left" charoff="50" valign="top">1? tumours</td> 
      <td align="center" charoff="50" valign="top">0/19</td> 
      <td align="left" charoff="50" valign="top">0/19</td> 
      <td align="left" charoff="50" valign="top">0/19</td> 
      <td align="left" charoff="50" valign="top">0/19</td> 
      <td align="left" charoff="50" valign="top">Activation MAPK pathway: MEK, ELK, ERK</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">Cell lines</td> 
      <td align="center" charoff="50" valign="top">1/10</td> 
      <td align="left" charoff="50" valign="top">0/10</td> 
      <td align="left" charoff="50" valign="top">0/10</td> 
      <td align="left" charoff="50" valign="top">0/10</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote3"> 
     <label>a</label> 
     <p>Not specified if samples were from primary or secondary tumours.</p> 
    </fn> 
    <fn id="tbfnote4"> 
     <label>b</label> 
     <p>All V599E.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
 </floats-wrap> 
</article>